Management of Antiphospholipid Antibody Syndrome: A Systematic Review
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
CONTEXT: Antiphospholipid antibodies are autoantibodies directed against proteins that bind to phospholipid. Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity. Patients with APS may be at increased risk of recurrent arterial or venous thrombosis or pregnancy loss. OBJECTIVE: To systematically review the evidence for treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. EVIDENCE ACQUISITION: Search of MEDLINE (1966 to November 2005) and Cochrane Library electronic databases (2005) and reference lists for randomized trials, meta-analyses of randomized trials, and prospective cohort studies of the treatment of thrombosis risk in patients with antiphospholipid antibodies or APS. Studies were selected on the basis of clinical relevance. EVIDENCE SYNTHESIS: Among patients with antiphospholipid antibodies, the absolute risk of developing new thrombosis is low (<1% per year) in otherwise healthy patients without prior thrombotic events, may be moderately increased (up to 10% per year) in women with recurrent fetal loss without prior thrombosis, and is highest (>10% in the first year) in patients with a history of venous thrombosis who have discontinued anticoagulant drugs within 6 months. Compared with placebo or untreated control, anticoagulation with moderate-intensity warfarin (adjusted to a target international normalized ratio [INR] of 2.0-3.0) reduces the risk of recurrent venous thrombosis by 80% to 90% irrespective of the presence of antiphospholipid antibodies and may be effective for preventing recurrent arterial thrombosis. No evidence exists that high-intensity warfarin (target INR, >3.0) is more effective than moderate-intensity warfarin. For patients with a single positive antiphospholipid antibody test result and prior stroke, aspirin and moderate-intensity warfarin appear equally effective for preventing recurrent stroke. Treatment issues that have not been addressed in clinical trials, or for which the evidence is conflicting, include the role of antithrombotic prophylaxis in patients with antiphospholipid antibodies without prior thrombosis, the optimal treatment of noncerebrovascular arterial thrombosis, recurrent thrombosis despite warfarin therapy, and treatment of women with antiphospholipid antibodies and recurrent fetal loss. CONCLUSIONS: In patients with APS, moderate-intensity warfarin is effective for preventing recurrent venous thrombosis and perhaps also arterial thrombosis. Aspirin appears to be as effective as moderate-intensity warfarin for preventing recurrent stroke in patients with prior stroke and a single positive test result for antiphospholipid antibody. The optimal treatment of other thrombotic aspects of APS needs to be addressed in well-designed prospective studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Cervera, R., Piette, J., Font, J., Khamashta, M. A., Shoenfeld, Y., Camps, M. T., Jacobsen, S., Lakos, G., Tincani, A., Kontopoulou‐Griva, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10187 · Cited by 2,156 · cited 12×
“Estimates of bleeding risk are derived from studies evaluating anticoagulant therapy in patients with APS.”
BackgroundInfluentialAnderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400050081016 · Cited by 1,669
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Harris, E. N., Boey, M. L., Mackworth-Young, C. G., Gharavi, A. E., Patel, B. M., Loizou, S., & Hughes, G. R. V. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91267-9 · Cited by 1,383
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972 · cited 1×
“Furthermore, a recent systematic review has questioned the association between isolated aCL and thrombosis.(7) We systematically reviewed laboratory testing, diagnostic criteria, and treatment of thrombosis in patients with antiphospholipid antibodies.”
BackgroundHorlocker, T. (2003) · Regional Anesthesia and Pain Medicine · doi:10.1053/rapm.2003.50046 · Cited by 921
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919 · cited 2×
“2).(53) In the second trial,(54) among 109 patients with APS who were randomized (89% had previous venous thrombosis) and followed up for a median duration of 3.”
BackgroundResultSelf-citationAsherson, R. A., Cervera, R., de Groot, P. G., Erkan, D., Boffa, M.-C., Piette, J.-C., Khamashta, M. A., Shoenfeld, Y., & Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) · Lupus · doi:10.1191/0961203303lu394oa · Cited by 865
Kutteh, W. H. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70610-5 · Cited by 803
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAntiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700 · cited 4×
“Patients with venous thrombosis generally have recurrent venous events and patients with arterial thrombosis have recurrent arterial events.(50,52) Risk of Bleeding.”
BackgroundInfluentialFINAZZI, G., MARCHIOLI, R., BRANCACCIO, V., SCHINCO, P., WISLOFF, F., MUSIAL, J., BAUDO, F., BERRETTINI, M., Testa, S., D'ANGELO, A., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01340.x · Cited by 585
Use of Antithrombotic Agents During Pregnancy
Bates, S. M., Greer, I. A., Hirsh, J., & Ginsberg, J. S. (2004) · Chest · doi:10.1378/chest.126.3_suppl.627s · Cited by 552
Schulman, S., Svenungsson, E., & Granqvist, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00060-6 · Cited by 497
Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant
Empson, M. B., Lassere, M., Craig, J. C., & Scott, J. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002859.pub2 · Cited by 486
(1992) · PubMed · Cited by 434
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment
Farquharson, R. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02165-8 · Cited by 427
Finazzi, G., Brancaccio, V., Moia, M., Ciavarella, N., Mazzucconi, M. G., Schinco, P., Ruggeri, M., Pogliani, E. M., Gamba, G., Rossi, E., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00060-5 · Cited by 427
Harris, E. N. (1990) · American Journal of Clinical Pathology · doi:10.1093/ajcp/94.4.476 · Cited by 414
Galli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-11-3334 · Cited by 413 · cited 1×
“The laboratory assay for these antibodies is not standardized, making comparison between studies difficult.(11) The clinical relevance of anti– 2-glycoprotein I antibodies also is uncertain, although there is some evidence that these antibodies are more specific for APS.”
Prednisone and Aspirin in Women with Autoantibodies and Unexplained Recurrent Fetal Loss
Laskin, C. A., Bombardier, C., Hannah, M. E., Mandel, F. P., Ritchie, K., Farewell, V., Farine, D., Spitzer, K., Fielding, L., Soloninka, C. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370302 · Cited by 412
Antiphospholipid Antibodies and venous thromboembolism
Ginsberg, J., Wells, P., Brill-Edwards, P., Donovan, D., Moffatt, K., Johnston, M., Stevens, P., & Hirsh, J. (1995) · Blood · doi:10.1182/blood.v86.10.3685.bloodjournal86103685 · Cited by 365 · cited 1×
“In comparison, the prevalence of antiphospholipid antibodies appears to be higher, in the range of 4% to 21%, among patients presenting with thrombosis.(31,32) The increased prevalence of antiphospholipid antibodies among patients with thrombosis suggests an association between antiphospholipid antibodies and thrombos…”
BackgroundEine serodiagnostische Reaktion bei Syphilis
Wassermann, A., Neisser, A., & Bruck, C. (1906) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1142018 · Cited by 361
Lockwood, C. J., Romero, R., Feinberg, R. F., Clyne, L. P., Coster, B., & Hobbins, J. C. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90522-x · Cited by 359
Rai, R. S., Clifford, K., Cohen, H., & Regan, L. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135907 · Cited by 301
Pattison, N. S., Chamley, L. W., Birdsall, M., Zanderigo, A. M., Liddell, H. S., & McDougall, J. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.106754 · Cited by 291
Prevalence, Follow-Up and Clinical Significance of the Anticardiolipin Antibodies in Normal Subjects
Vila, P., Hernández, M. C., López-Fernández, M. F., & Batlle, J. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648840 · Cited by 280
Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy
YASUDA, M. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00247-o · Cited by 245
PREDNISONE AND ASPIRIN IN WOMEN WITH AUTOANTIBODIES AND UNEXPLAINED RECURRENT FETAL LOSS
Askin, C. A. A. L., Ombardier, C. L. B., Annah, M. A. E. H., Andel, P. M., Itchie, R., Arewell, V. E. F., Arine, D. A. F., Pitzer, K., Ielding, L. Y. F., Oloninka, A. S., et al. (1997) · Cited by 237
Antiphospholipid antibodies and fetal death
OSHIRO, B., SILVER, R., SCOTT, J., YU, H., & WAREBRANCH, D. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00498-x · Cited by 230
Antiphospholipid antibodies in pregnancy: prevalence and clinical associations
Pattison, N. S., Chamley, L. W., McKay, E. J., Liggins, G. C., & Butler, W. S. (1993) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1993.tb15105.x · Cited by 229
Brandt, J. T., Barna, L. K., & Triplett, D. A. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649988 · Cited by 228
Antiphospholipid Antibodies in Predicting Adverse Pregnancy Outcome: A Prospective Study
Lynch, A., Marlar, R., Murphy, J., Davila, G., Santos, M., Rutledge, J., & Emlen, W. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-6-199403150-00004 · Cited by 222
Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population
Shi, W., Krilis, S. A., Chong, B. H., Gordon, S., & Chesterman, C. N. (1990) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1990.tb01025.x · Cited by 196
Erkan, D., Merrill, J. T., Yazici, Y., Sammaritano, L., Buyon, J. P., & Lockshin, M. D. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1466::aid-art242>3.0.co;2-c · Cited by 193
Wahl, D. G., Guillemin, F., de Maistre, E., Perret-Guillaume, C., Lecompte, T., & Thibaut, G. (1998) · Lupus · doi:10.1191/096120398678919688 · Cited by 185
Allegri, F., Sanmarco, M., Cinquini, M., Taglietti, M., Balestrieri, G., Koike, T., Ichikawa, K., Meroni, P., Boffa, M. C., & Tincani, A. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616089 · Cited by 183
Out, H. J., Bruinse, H. W., Christiaens, G. C. M. L., van Vliet, M., de Groot, P. G., Nieuwenhuis, H. K., & Derksen, R. H. W. M. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)91619-6 · Cited by 177
Thrombosis and Systemic Lupus Erythematosus: The Hopkins Lupus Cohort Perspective
Petri, M. (1996) · Scandinavian Journal of Rheumatology · doi:10.3109/03009749609069986 · Cited by 176
Tulppala, M., Marttunen, M., Soderstrom-Anttila, V., Foudila, T., Ailus, K., Palosuo, T., & Ylikorkala, O. (1997) · Human Reproduction · doi:10.1093/humrep/12.7.1567 · Cited by 172
A prospective study of antibodies to β2‐glycoprotein I and prothrombin, and risk of thrombosis
FORASTIERO, R., MARTINUZZO, M., POMBO, G., PUENTE, D., ROSSI, A., CELEBRIN, L., BONACCORSO, S., & AVERSA, L. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01295.x · Cited by 170
Pathophysiology of the antiphospholipid syndrome
de Groot, P. G., & Derksen, R. H. W. M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01359.x · Cited by 147
Treatment of pregnant patients with antiphospholipid syndrome
Tincani, A., Branch, W. D., Levy, R. A., Pietté, J. C., CARP, H. J. A., Rai, R., Khamashta, M. A., & Shoenfeld, Y. (2003) · Lupus · doi:10.1191/0961203303lu393oa · Cited by 132
Do low-risk pregnant women with antiphospholipid antibodies need to be treated?
Cowchock, S., & Reece, E. A. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70409-5 · Cited by 127
Long, A. A., Ginsberg, J. S., Brill-Edwards, P., Johnston, M., Turner, C., Denburg, J. A., Bensen, W. G., Cividino, A., Andrew, M., & Hirsh, J. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646452 · Cited by 120 · cited 4×
“Depending on the assay, antiphospholipid antibodies are reported in up to 10% of healthy individuals and in 30% to 50% of patients with SLE.(6) Antiphospholipid antibodies are more common in patients with thrombosis but a causal association is unproven and the clinical relevance of transient or low titer antiphospholi…”
BackgroundInfluentialCardiac involvement in the antiphospholipid syndrome
Tenedios, F., Erkan, D., & Lockshin, M. D. (2005) · Lupus · doi:10.1191/0961203305lu2202oa · Cited by 119
Janardhan, V., Wolf, P. A., Kase, C. S., Massaro, J. M., D’Agostino, R. B., Franzblau, C., & Wilson, P. W. F. (2004) · Stroke · doi:10.1161/01.str.0000117575.48205.2d · Cited by 116
Prophylaxis of the antiphospholipid syndrome: a consensus report
Alarcón-Segovia, D., Boffa, M., Branch, W. D., Cervera, R., Gharavi, A. E., Khamashta, M. A., Shoenfeld, Y., Wilson, W., & Roubey, R. A. S. (2003) · Lupus · doi:10.1191/0961203303lu388oa · Cited by 102
Revisiting the anticardiolipin test and its standardization
Harris, E. N., & Pierangeli, S. S. (2002) · Lupus · doi:10.1191/0961203302lu202cr · Cited by 101
Management of venous thromboembolism during pregnancy
Ginsberg, J. S., & Bates, S. M. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00307.x · Cited by 93
Rintelen, C., Vormittag, R., Sailer, T., Lehr, S., Quehenberger, P., Rumpold, H., Male, C., & Pabinger, I. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01394.x · Cited by 88
Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002
Brey, R. L., Chapman, J., Levine, S. R., Ruiz‐Irastorza, G., Derksen, R. H. W. M., Khamashta, M. A., & Shoenfeld, Y. (2003) · Lupus · doi:10.1191/0961203303lu390oa · Cited by 87
The Italian Registry of Antiphospholipid Antibodies.
Finazzi, G. (1997) · PubMed · Cited by 86
Satoh, A., Suzuki, K., Takayama‐Muromachi, E., Kojima, K., Hidaka, T., Kawakami, M., Matsumoto, I., & Ohsuzu, F. (1999) · PubMed · Cited by 67
Tripodi, A., Chantarangkul, V., Clerici, M., & Mannucci, P. M. (2002) · PubMed · Cited by 62
Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant
de Groot, P. G., Horbach, D. A., Simmelink, M. J. A., van Oort, E., & Derksen, R. H. W. M. (1998) · Lupus · doi:10.1177/096120339800700208 · Cited by 56
Lillicrap, D., Pinto, M., Benford, K., Ford, P. M., & Ford, S. E. (1990) · American Journal of Clinical Pathology · doi:10.1093/ajcp/93.6.771 · Cited by 49
Ae, G., Sammaritano, L. R., Wen, J., Miyawaki, N., Jh, M., Zarrabi, M. H., & Lockshin, M. D. (1994) · PubMed · Cited by 46
Primary Prevention of Thrombosis in Subjects with Positive Antiphospholipid Antibodies
Khamashta, M. A. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0421 · Cited by 45
Dentali, F., Manfredi, E., Crowther, M. A., & Ageno, W. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01516.x · Cited by 44
Self-citationValue of autoantibodies to beta2-glycoprotein 1 in the diagnosis of antiphospholipid syndrome
AUDRAIN, M. A. P., El-Kouri, D., Hamidou, M. A., Mioche, L., Ibara, A., Langlois, M.-L., & Muller, J.-Y. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.5.550 · Cited by 39
Evidence based treatment of the antiphospholipid syndrome
Crowther, M. A., & Wislöff, F. (2004) · Thrombosis Research · doi:10.1016/j.thromres.2004.06.041 · Cited by 34
Self-citationAnticardiolipin antibodies levels in healthy pregnant and non-pregnant woman
Tsapanos, V. S., Kanellopoulos, N., Cardamakis, E., FOTOPOULOS, A. D., TZINGOUNIS, V. A., Schinas, V., & Kondakis, X. G. (2000) · Archives of Gynecology and Obstetrics · doi:10.1007/s004040050007 · Cited by 19
Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis
Ost, D., Tepper, J., Mihara, H., Lander, O., Heinzer, R., & Fein, A. (2005) · JAMA · doi:10.1001/jama.294.6.706 · Cited by 3
Wilson (1999) · doi:10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f
Cited by
Saposnik, G., Barinagarrementeria, F., Brown, R. D., Bushnell, C. D., Cucchiara, B., Cushman, M., deVeber, G., Ferro, J. M., & Tsai, F. Y. (2011) · Stroke · doi:10.1161/str.0b013e31820a8364 · Cited by 1,970
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Self-citationGuidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506
Self-citation
Metadata
- Authors
- Lim, W., Crowther, M. A., & Eikelboom, J. W.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-03-01
- Volume
- 295
- Issue
- 9
- Pages
- 1050
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2155433659
- Cited by
- 448
- References
- 73
- FWCI
- 29.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.